Drugs and Devices

FDA approves first therapy for high-risk neuroblastoma

On March 10, the U.S. Food and Drug Administration (FDA) approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares